Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A3H2101
Wed, 14.06.2023
aap Implantate AG
The Management Board and Supervisory Board of aap Implantate AG ("aap" or the "Company") have, in the run-up to the adoption of the notice convening the Annual General Meeting to be held on July 25, 2023, intensively considered the Company's situation, its future development and the current and assumed macroeconomic environment in the further cours [ … ]
Thu, 25.05.2023
aap Implantate AG
CFO Marek Hahn recently informed the company of his wish not to accept the offered contract extension and to terminate his Executive Board activities as of Dec. 31, 2023
Dr. Nathalie Krebs, Chairwoman of the Supervisory Board, praises Hahn's "dedication, strategic clarity and leadership"
CEO Rubino di Girolamo and COO Agnieszka Mierzejewska wi [ … ]
Thu, 25.05.2023
aap Implantate AG
CFO Marek Hahn recently informed the company of his wish not to accept the offered contract extension and to terminate his Executive Board activities as of Dec. 31, 2023
Dr. Nathalie Krebs, Chairwoman of the Supervisory Board, praises Hahn's "dedication, strategic clarity and leadership"
CEO Rubino di Girolamo and COO Agnieszka Mierzejewska wi [ … ]
Mon, 15.05.2023
aap Implantate AG
Sales: EUR 3.0 million (+3 % yoy; CER[1] : +2 % yoy); LATAM (+55 % yoy) and USA (+15 % yoy) with significant double-digit growth; EMEA with -9 % yoy remains below expectations
EBITDA unchanged year-on-year at EUR -0.5 million in cost- and interest-rate-inflationary environment; operating cash flow +74 % year-on-year
Silver: Clinical trial resu [ … ]
Mon, 15.05.2023
aap Implantate AG
Sales: EUR 3.0 million (+3 % yoy; CER[1] : +2 % yoy); LATAM (+55 % yoy) and USA (+15 % yoy) with significant double-digit growth; EMEA with -9 % yoy remains below expectations
EBITDA unchanged year-on-year at EUR -0.5 million in cost- and interest-rate-inflationary environment; operating cash flow +74 % year-on-year
Silver: Clinical trial resu [ … ]
Fri, 28.04.2023
aap Implantate AG
Sales: EUR 11.5 million (-6 % yoy; CER[1] : -9 % yoy); markets generally in difficult environment with mixed results; USA in H2/2022 with solid growth and excluding one-off effects +16 % yoy
EBITDA: EUR -1.7 million (FY/2021: EUR -0.8 million); operating cash flow +23 % yoy
Silver: Release revised study protocol in Q4/2022 with restart study i [ … ]
Fri, 28.04.2023
aap Implantate AG
Sales: EUR 11.5 million (-6 % yoy; CER[1] : -9 % yoy); markets generally in difficult environment with mixed results; USA in H2/2022 with solid growth and excluding one-off effects +16 % yoy
EBITDA: EUR -1.7 million (FY/2021: EUR -0.8 million); operating cash flow +23 % yoy
Silver: Release revised study protocol in Q4/2022 with restart study i [ … ]
Mon, 03.04.2023
aap Implantate AG
aap Implantate AG (“aap”) announces that its US subsidiary aap Implants Inc has been awarded a group purchasing agreement for the “Small Joint Implants – Upper Extremities” “Small Joint Implants - Lower Extremities, Podiatry Products and Accessories” portfolio with Premier, Inc., effective as of March 1, 2023. The agreement allows Premier members, [ … ]
Mon, 03.04.2023
aap Implantate AG
aap Implantate AG (“aap”) announces that its US subsidiary aap Implants Inc has been awarded a group purchasing agreement for the “Small Joint Implants – Upper Extremities” “Small Joint Implants - Lower Extremities, Podiatry Products and Accessories” portfolio with Premier, Inc., effective as of March 1, 2023. The agreement allows Premier members, [ … ]
Tue, 21.03.2023
aap Implantate AG
aap Implantate AG (“aap”) announces that its new system LOQTEQ® VA Elbow 2.7/3.5 has been cleared by the US-American Food and Drug Administration (FDA). The Company plans to launch the system LOQTEQ® VA Elbow 2.7/3.5 in the fourth quarter of 2023 in the United States and in other markets that accept FDA clearances. The system enables flexible treat [ … ]